Chronic Pain Market is expected to reach US$ 142.28 Billion by 2033 | Major key players - Pfizer Inc., GSK plc, Bayer AG, Novartis AG.

Market Size and Growth:

The Chronic Pain Market Size reached US$79.96 Billion in 2024 and is expected to reach US$142.28 Billion by 2033, growing at a CAGR of 7.5 % during the forecast period 2025-2033. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/chronic-pain-market?sz

The Chronic Pain Market refers to the healthcare ecosystem focused on diagnosing, managing, and treating long-lasting pain conditions that persist for more than three months. It includes pharmaceuticals, medical devices, digital therapeutics, and interventional procedures aimed at improving patient quality of life. The market is driven by rising disease prevalence, aging populations, and increasing demand for personalized, non-opioid pain management solutions.

United States: Recent Developments of Chronic Pain Market

✅ October 2025: The FDA issued new guidance to expand non-opioid options for chronic pain management and required safety labeling changes on drugs used in pain treatment.

✅ November 2025: The market showed strong prescription volumes for both opioids and non-opioid solutions, with drug segment estimated at USD 12.8 billion and devices segment at USD 6.8 billion, reflecting investment in advanced device-based therapies and integration of personalized pain management programs.

✅ December 2025: Major players in the chronic pain treatment market are adopting strategic initiatives and innovations in therapy development, with growing emphasis on neuromodulation technologies and regulatory approvals for new therapies.

Europe: Recent Developments of Chronic Pain Market

✅ October 2025: Increasing R&D efforts are driving the manufacture of effective devices and medications for chronic pain, supported by government initiatives and growing awareness among healthcare professionals and patients.

✅ November 2025: The European chronic pain market is expanding due to rising geriatric population, increasing prevalence of chronic conditions, and collaborations between pharmaceutical and medical device companies to develop innovative solutions.

✅ December 2025: Biocon Biologics secured market entry for Denosumab biosimilars in Europe, enhancing treatment options for chronic pain starting December 2, 2025.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/chronic-pain-market?sz

Key FDA / Regulatory Approvals in 2025:

✅ Journavx (suzetrigine) - FDA approval (Jan 30, 2025).
Vertex's first-in-class non-opioid NaV1.8 inhibitor was approved for moderate-severe acute pain (post-surgical/acute indications). It's widely discussed as a milestone for non-opioid analgesics, but its approval was not for chronic pain and clinical signal for chronic indications has been mixed - so its immediate commercial impact on the chronic-pain market is indirect (platform/validation effect).

✅ FDA draft guidance: "Development of Non-Opioid Analgesics for Chronic Pain" (published Sept 2025 / Federal Register notice Sept 11, 2025).
The FDA issued draft guidance to clarify expectations for phase-3 program design for non-opioid therapies targeting chronic pain, aiming to accelerate development and broaden non-opioid options while addressing opioid-related harm. This is an important regulatory signal shaping trial designs and commercial strategy for companies pursuing chronic-pain approvals.

✅ Regulatory designations / development milestones (examples in 2025).
Several experimental chronic/neuropathic pain programs received expedited designations or progressed in clinic in 2025 (for example, Sangamo's ST-503 program received FDA Fast Track attention for chronic neuropathic pain updates during 2025). These designations increase the chance of faster reviews and higher investor interest in pain assets.

✅ Avance - FDA approval of a peripheral nerve scaffold for sensory nerve discontinuities (2025).
The agency granted approval for a nerve scaffold product intended for certain sensory/mixed nerve indications, a device-side regulatory event that can affect surgical/repair-related pain management pathways.

Major Mergers & Acquisitions in 2025:

✅ Eli Lilly → acquired SiteOne Therapeutics (deal announced May 2025; up to ~$1.0B).
Lilly bought SiteOne (whose lead programs target Nav channels/other non-opioid pain mechanisms) to expand its pain pipeline and compete with companies developing NaV1.x inhibitors - a strategic move that consolidates R&D around ion-channel pain targets.

✅ Boston Scientific → agreement to acquire Nalu Medical (announced Oct 17, 2025; transaction disclosed in 2025 materials).
Boston Scientific's deal (neurostimulation/implantable device maker focused on minimally invasive solutions for chronic pain) is an important med-tech consolidation that strengthens neuromodulation offerings for persistent pain. (Announcement date: Oct 17, 2025 - included because it was executed/planned within 2025 reporting.)

✅ Scilex / SPAC / Semnur combination and other consolidations (mid-2025 - Sept approvals).
Scilex (pain-focused company) completed corporate combinations and restructuring in 2025 to form Semnur Pharmaceuticals (business combination approvals in Sept 2025), reflecting active dealmaking among specialty pain players and consolidators building non-opioid portfolios.

✅ Other notable transactions / smaller deals: Ligand's Pelthos combination and similar bio/medtech tie-ups (announced 2025) represent additional financing and consolidation activity in firms developing pain-relevant products.

Major Players:

Key companies in the Chronic Pain market include:

Pfizer Inc.
Johnson & Johnson Services, Inc.
GSK plc
Bayer AG
Novartis AG
Endo, Inc.
Viatris Inc.
Eli Lilly and Company.
Teva Pharmaceutical Industries Ltd.
Reckitt Benckiser Group PLC

Segments Covered in the Chronic Pain Market:

By Type: Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post-Operative Pain, Migraine, Others.

By Treatment Type: Drug Class, Devices.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Chronic Pain Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=chronic-pain-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Chronic Pain market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Chronic Pain Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Chronic Pain market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Chronic Pain Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Chronic Pain market?

➠ Who are the global key manufacturers of the Chronic Pain Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Chronic Pain market opportunities and threats faced by the vendors in the global Chronic Pain Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Chronic Pain market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.